WAYNE, Pa. and ROCKVILLE, Md., Aug. 12, 2024 (GLOBE NEWSWIRE) — Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and financial results for the second quarter of 2024.
“The team has made outstanding progress in a short amount of time toward initiating the Phase 2 LOTUS Trial, as highlighted by the activation of the IND in July,” said Dr. Garry Neil, Chief Executive Officer and Chairman of the Board. “Furthermore, the Company is immediately benefiting from the addition of Mittie and Paul to the leadership team as CMO and CLO, respectively. Their deep expertise and leadership experience will guide us as we focus on initiating the LOTUS Trial, as well as the evaluation and announcement of a second indication, both of which we believe are on track for the second half of the year.”
Program Updates and Milestones:
- AVTX-009: Anti-IL-1β monoclonal antibody (mAb) targeting inflammatory diseases.
- Avalo is pursuing the development of AVTX-009 in hidradenitis suppurativa (HS).
- In July 2024, Avalo announced that the Investigational New Drug Application (IND) for the treatment of HS is active, permitting Avalo to commence its Phase 2 LOTUS Trial in patients with HS.
- Avalo expects to enroll the first patient in its global Phase 2 LOTUS Trial in the second half of 2024.
- In addition to hidradenitis suppurativa, Avalo plans to develop AVTX-009 in at least one other chronic inflammatory indication.
Second Quarter 2024 Financial Update:
As of June 30, 2024, Avalo had $93.4 million in cash and cash equivalents. Net cash used in operating activities was $22.5 million for the six months ended June 30, 2024, which includes a $7.5 million milestone payment to AlmataBio, Inc. pursuant to the acquisition in the first quarter. The Company’s current cash on hand is expected to fund operations into 2027.
For the six months ended June 30, 2024, Avalo generated a net loss of $22.8 million, representing a $4.7 million increase in net loss as compared to the same period in 2023. Total operating expenses increased by $25.3 million and was primarily driven by the recognition of $27.6 million of acquired in-process research and development (“IPR&D”) expense from the acquisition of AlmataBio, Inc. in the first quarter of 2024. The increase in operating expenses was partially offset by a $21.7 million increase in other income, net which largely related to the loss associated with warrant liability from the private placement in the first quarter being more than offset by the warrant liability change in fair value in the second quarter. Net loss per share of common stock decreased as a result of the increase in the shares outstanding from the second quarter of 2023, partially offset by the increase in net loss.
| Consolidated Balance Sheets (In thousands, except share and per share data) |
||||||||
| June 30, 2024 | December 31, 2023 | |||||||
| (unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 93,426 | $ | 7,415 | ||||
| Other receivables | 33 | 136 | ||||||
| Prepaid expenses and other current assets | 2,435 | 843 | ||||||
| Restricted cash, current portion | — | 1 | ||||||
| Total current assets | 95,894 | 8,395 | ||||||
| Property and equipment, net | 1,780 | 1,965 | ||||||
| Goodwill | 10,502 | 10,502 | ||||||
| Restricted cash, net of current portion | 131 | 131 | ||||||
| Total assets | $ | 108,307 | $ | 20,993 | ||||
| Liabilities, mezzanine equity and stockholders’ (deficit) equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 654 | $ | 446 | ||||
| Accrued expenses and other current liabilities | 7,888 | 4,172 | ||||||
| Warrant liability | 82,855 | — | ||||||
| Contingent consideration | 5,000 | — | ||||||
| Total current liabilities | 96,397 | 4,618 | ||||||
| Royalty obligation | 2,000 | 2,000 | ||||||
| Deferred tax liability, net | 168 | 155 | ||||||
| Derivative liability | 10,710 | 5,550 | ||||||
| Other long-term liabilities | 1,183 | 1,366 | ||||||
| Total liabilities | 110,458 | 13,689 | ||||||
| Mezzanine equity: | ||||||||
| Series C Preferred Stock—$0.001 par value; 34,326 and 0 shares of Series C Preferred Stock authorized at June 30, 2024 and December 31, 2023, respectively; 22,358 and 0 shares of Series C Preferred Stock issued and outstanding at June 30, 2024 and December 31, 2023, respectively | 11,457 | — | ||||||
| Series D Preferred Stock—$0.001 par value; 1 and 0 shares of Series D Preferred Stock authorized at June 30, 2024 and December 31, 2023, respectively; 1 and 0 shares of Series D Preferred Stock issued and outstanding at June 30, 2024 and December 31, 2023, respectively | — | — | ||||||
| Series E Preferred Stock—$0.001 par value; 1 and 0 shares of Series E Preferred Stock authorized at June 30, 2024 and December 31, 2023, respectively; 1 and 0 shares of Series E Preferred Stock issued and outstanding at June 30, 2024 and December 31, 2023, respectively | — | — | ||||||
| Stockholders’ (deficit) equity: | ||||||||
| Common stock—$0.001 par value; 200,000,000 shares authorized at June 30, 2024 and December 31, 2023; 1,034,130 and 801,746 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively | 1 | 1 | ||||||
| Additional paid-in capital | 344,352 | 342,437 | ||||||
| Accumulated deficit | (357,961 | ) | (335,134 | ) | ||||
| Total stockholders’ (deficit) equity | (13,608 | ) | 7,304 | |||||
| Total liabilities, mezzanine equity and stockholders’ (deficit) equity | $ | 108,307 | $ | 20,993 | ||||
The consolidated balance sheets as of June 30, 2024 and December 31, 2023 have been derived from the reviewed and audited financial statements, respectively, but do not include all of the information and footnotes required by accounting principles accepted in the United States for complete financial statements.
| Consolidated Statements of Operations
(In thousands, except per share data) |
||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Revenues: | ||||||||||||||||
| Product revenue, net | $ | — | $ | 643 | $ | — | $ | 1,117 | ||||||||
| Total revenues, net | — | 643 | — | 1,117 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Cost of product sales | 343 | 708 | 263 | 1,259 | ||||||||||||
| Research and development | 4,601 | 4,658 | 6,716 | 10,667 | ||||||||||||
| Acquired in-process research and development | 103 | — | 27,641 | — | ||||||||||||
| General and administrative | 4,528 | 2,427 | 7,721 | 5,134 | ||||||||||||
| Total operating expenses | 9,575 | 7,793 | 42,341 | 17,060 | ||||||||||||
| (9,575 | ) | (7,150 | ) | (42,341 | ) | (15,943 | ) | |||||||||
| Other income (expense): | ||||||||||||||||
| Excess of initial warrant fair value over private placement proceeds | — | — | (79,276 | ) | — | |||||||||||
| Change in fair value of warrant liability | 112,046 | — | 112,046 | — | ||||||||||||
| Private placement transaction costs | — | — | (9,220 | ) | — | |||||||||||
| Change in fair value of derivative liability | (5,040 | ) | (40 | ) | (5,160 | ) | (220 | ) | ||||||||
| Interest income (expense), net | 1,039 | (996 | ) | 1,138 | (1,945 | ) | ||||||||||
| Other expense, net | — | — | — | (25 | ) | |||||||||||
| Total other income (expense), net | 108,045 | (1,036 | ) | 19,528 | (2,190 | ) | ||||||||||
| Income (loss) before taxes | 98,470 | (8,186 | ) | (22,813 | ) | (18,133 | ) | |||||||||
| Income tax expense | 7 | 7 | 14 | 15 | ||||||||||||
| Net income (loss) | $ | 98,463 | $ | (8,193 | ) | $ | (22,827 | ) | $ | (18,148 | ) | |||||
| Net income (loss) per share of common stock1: | ||||||||||||||||
| Basic | $ | 4.21 | $ | (140.73 | ) | $ | (24.11 | ) | $ | (338.85 | ) | |||||
| Diluted | $ | (14.07 | ) | $ | (140.73 | ) | $ | (30.63 | ) | $ | (338.85 | ) | ||||
1 Amounts for prior periods presented have been retroactively adjusted to reflect the 1-for-240 reverse stock split effected on December 28, 2023.
The unaudited consolidated statements of operations for the three and six months ended June 30, 2024 and 2023 have been derived from the reviewed financial statements, but do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.
About Avalo Therapeutics
Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Avalo also has two additional drug candidates, which include quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). For more information about Avalo, please visit www.avalotx.com.
About AVTX-009
AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology.
About the LOTUS Trial
The LOTUS Trial is a randomized, double-blind, placebo-controlled, parallel-group Phase 2 trial with two AVTX-009 dose regimens to evaluate the efficacy and safety of AVTX-009 in approximately 180 adults with moderate to severe hidradenitis suppurativa. The primary efficacy endpoint is the proportion of subjects achieving Hidradenitis Suppurativa Clinical Response (HiSCR75) at Week 16. Subjects will be randomized (1:1:1) to receive either one of two doses of AVTX-009 or placebo.
About Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by painful nodules, abscesses, and tunnels that form in areas of the body such as the armpits, groin, and buttocks, severely impacting the quality of life of affected individuals.1 HS is often underdiagnosed or misdiagnosed and therefore estimates of HS vary between 0.2-1.7% of the population worldwide.2-5 The exact cause of HS is not fully understood but is believed to involve a combination of genetic, hormonal, and environmental factors. While advances in treatment have been made, limited treatment options are available. IL-1β plays a crucial role in the inflammatory cascade underlying HS, contributing to tissue damage, inflammation, and disease progression. Given the involvement of IL-1β in the inflammatory process of HS, we believe therapies that target IL-1β offer a potential treatment option for HS.
